

IDS/ #10
3/18/02
PATENT
TECH CENTER 1600/2900
RECEIVED
MAR 14 2002

Customer No. 22352
Attorney Docket No. 8702.000201-000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
MANJUNATH et al.) Group Art Unit: 1644
)
Application No.: 09/904,710) Examiner: Not Yet Assigned
)
Filed: July 12, 2001)
)
For: INHIBITION OF DIFFERENTIATION)
OF CYTOTOXIC T-CELLS BY P-)
SELECTIN LIGAND (PSGL))
ANTAGONISTS)

Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicant brings to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Each document listed in this Information Disclosure Statement was first cited in a communication from the European Patent Office in a counterpart foreign application.

Copies of the listed documents are attached.

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.



LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicant(s) determine(s) that the cited document(s) do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: March 8, 2002

By: Leslie A. McDonell
Leslie A. McDonell
Reg. No. 34,872

INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011

RECEIVED
MAR 14 2002
TECH CENTER 1600/2900

Atty. Docket No.	8702.0002-01	Serial No.	09/904,710
Applicant	MANJUNATH et al.		
Filing Date	July 12, 2001	Group:	1644

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
WO 94/10309	11 May 1994	PCT	C12N	15/12	YES
WO 94/11498	26 May 1994	PCT	C12N	15/10	YES
WO 97/06176	20 February 1997	PCT	C07H	03/06	YES

	Supplementary Partial European Search Report, Application No. 99 96 4950, dated 17 October 2001
	Vachino, G., et al., "P-Selectin Glycoprotein Ligand-1 Is the Major Counter-receptor for P-selectin on Stimulated T Cells and Is Widely Distributed in Non-functional Form on Many Lymphocytic Cells," <i>J. Biol. Chem.</i> , Vol. 270, No. 37: 21966-21974; September 15, 1995.
	Wilkins, P.P., et al., "Tyrosine Sulfation of P-selectin Glycoprotein Ligand-1 Is Required for High Affinity Binding to P-selectin," <i>J. Biol. Chem.</i> , Vol. 270, No. 39:22677-22680; September 29, 1995.

Examiner	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce